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APBI = accelerated partial breast irradiation; CTV = clinical target volume; IORT = intraoperative radiotherapy; PBRT = partial breast radiotherapy;
PBI = partial breast irradiation; WBRT = whole breast radiotherapy.
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Abstract
Modern breast cancer radiotherapy aims to increase
uncomplicated cure rates. A priority is reduction of late effects
which include chronic chest wall or breast pain, poor cosmesis,
and cardiac toxicity. As breast screening detects early cancers we
may be able to safely restrict irradiation postlumpectomy to the
tumour bed with a margin, defining a ‘partial breast’ target volume
for treatment. Differing technical approaches to partial breast
irradiation are being evaluated in phase III studies with standard
whole breast irradiation. These include intra-operative single
doses, hypo-fractionated accelerated brachytherapy, and LINAC
(linear accelerator)-based three-dimensional external beam therapy.
Introduction
Breast conservation has become the standard of care for
women with small cancers who wish to avoid mastectomy.
During the past 20 years carefully conducted clinical studies
have demonstrated the efficacy of lumpectomy followed by
radiotherapy in achieving survival levels equivalent to those
with mastectomy, with major improvements in body image
and psychosexual functioning [1]. The price of such progress
has not been cheap, because the change in practice has
been a major resource issue for many oncology services
where health care planning failed to predict the demanding
(and appropriate) increase in use of radiotherapy for most
common cancers.
The key issue, then, remains how do we maintain excellent
breast conservation rates after lumpectomy, while reducing
the morbidity of whole breast radiotherapy (WBRT)? Long-
term breast or chest wall pain and poor cosmesis in a
relatively small proportion of patients has always been
considered by the majority of women to be an acceptable
trade-off against preservation of the breast. More serious
concerns regarding long-term efficacy emerged from the
Early Breast Trialists overview [2], which confirmed excess
cardiac events in left-sided breast cancers.
One approach to reducing late radiotherapy morbidity with
WBRT has been to seek to define those patients with small,
node-negative cancers, who are most likely to have been
‘cured’ by lumpectomy alone! This philosophy originally
gained support from randomized trial evidence indicating that
there was no apparent difference in survival rates after
lumpectomy with or without radiotherapy. Recent
publications support the notion that WBRT after lumpectomy
produces excellent local control in around 96% of patients at
5 years, with no difference in risk for distant metastases or
survival. Questions have now been raised regarding the level
of benefit from WBRT in women older than 70 years, and in
those with tumours <2 cm that are oestrogen receptor
positive and node negative, although it is clear that 5 years of
follow up is not adequate for evaluating overall efficacy [3].
Even with careful case selection it is likely that with continued
follow up local failures after lumpectomy alone will continue
to rise. Keisch [4] cited the Milan QUART (Quadrantectomy,
Axillary Dissection and Radiotherapy) study [5], which found
evidence that patients receiving generous ‘quadrantic’
surgery still enjoy further benefit from radiotherapy with
sufficient follow up. However, another interpretation of the
study is that nonsurgical quadrant therapies (i.e.
intraoperative radiotherapy [IORT]) are equally likely to
prejudice local control rates with sufficient follow up, unless
cases are so well selected that they are likely to have already
been cured by their surgery. As the average life expectancy of
women approaches 80 years in most Western countries,
even selecting an older cohort to omit WBRT may have an
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impact on future breast conservation rates and possibly on
overall disease-free survival.
A much more challenging, alternative approach to selective
avoidance of WBRT has been to refine adjuvant breast radio-
therapy techniques. A number of investigators are actively re-
exploring tumour bed irradiation (partial breast radiotherapy
[PBRT]) combined with accelerated, hypofractionated therapy.
We should remember that the philosophy of PBRT was
previously explored and discarded when interstitial implants
and electron beam approaches failed to generate adequate
local control rates with acceptable cosmesis [6,7]. However,
several key clinical factors and technical advances now drive
an exciting reappraisal of how best to use adjuvant
radiotherapy in early breast cancer. These include an
increasing proportion of women with early and in situ breast
cancer, an awareness of the potential for late cardiac toxicity,
and the health economics of protracted treatment courses with
significant equipment and human resource needs. Are faster,
fewer fractions delivered to partial breast volumes the solution?
How can we localize the tumour cavity after
lumpectomy?
As a result of breast screening, we are seeing increased
numbers of small cancers with better prognosis. In some
centres ductal carcinoma in situ constitutes 20–30% of all
new cancers. With increasingly compelling evidence that the
main effect of WBRT is to reduce significantly local
recurrence in the index quadrant, without a measurable
impact on subclinical foci in other sectors, we need to
redefine the clinical target volume (CTV) after lumpectomy.
One of the principle concerns in defining practice for partial
breast irradiation (PBI) is lack of experience in defining a CTV
after lumpectomy. This is compounded by the fact that the
surgery is not performed in the plane of the breast ductal
system, creating potential to have varying three-dimensional
clearance following tumourectomy. Surgical clips appear to
be the current ‘gold standard’ for defining the resection
margins, but the frequency and extent of clip migration have
yet to be fully defined, posing problems for external beam
PBRT in particular.
What is the appropriate margin for a clinical
target volume?
The appropriate CTV for PBI is subject to considerable debate;
clinicians have concluded empirically that defining a treatment
margin of 10–20 mm should encompass any microscopic
margins in the ‘majority’ of patients; this will need to be proven
to be the standard of practice in this area in prospective
studies, in which close attention is paid to documentation of
surgical margins. Concern over the need to avoid skin in the
high-dose region, with potential for necrosis or telangectasia,
have led to empirical adoption of 5 mm clearance from CTV to
skin, resulting in the potential for inadequate anterior margin
therapy without careful case selection.
Can we treat partial breast irradiation
volumes reproducibly?
In addition to reservations regarding the definition of optimal
planning target volume in accelerated partial breast irradiation
(APBI), a further concern relates to reproducibility and
verification of fractionated courses. Clearly, this is mostly a
concern for external beam PBI rather than brachytherapy-
based PBI. In their study, Frazier and coworkers [8] analyzed
anterior–posterior motion of medial and lateral field borders
between normal inhalation and exhalation using computed
tomography coupled with automatic breathing control.
Movement ranged from 0.6 to 0.9 cm on these borders. In a
more recent study of target motion using surgical clips to
define the lumpectomy cavity in seven cases [8] the maximal
clip displacement with respiration ranged from 3 to 9 mm,
with a median of 6 mm. The investigators concluded that
symmetrically expanding the free-breathing CTV by 5 mm
would be sufficient to account for target motion in most
patients. It proved more difficult to allow for additional
elements of geometrical uncertainty (e.g. patient position
between fractions), and they concluded that a CTV to
planning target volume margin of 10 mm would be more likely
to guarantee target coverage. Although issues remain
regarding reproducibility, a major limitation of this approach
remains the significant dosimetry and LINAC (linear
accelerator) resources required to deliver fractionated
external beam-based conformal PBI, and constraints required
to achieve acceptable lung, cardiac and contralateral breast
doses. Although intensity-modulated radiotherapy has
produced significant improvements in dose delivery in several
tumour types, it remains far from clear that it can improve
uncomplicated breast cancer local control, largely because of
concerns over increased contralateral breast dose with
multiple beam delivery around the thorax. If reduction in
unnecessary cardiac dosing were the sole concern, then
‘mini-tangent’ conventional beams avoiding the lower breast
pole or incorporation of cardiac beam shaping would achieve
the objective in upper pole cancers very simply [9].
Partial breast irradiation is feasible, but is it a
major therapeutic advance? Is biology the key?
Techniques for APBI include LINAC-based three-dimensional
conformal external beam therapy [10], brachytherapy [11],
and intraoperative, single fraction treatment. The latter two
approaches are being evaluated in two randomized studies
against WBRT in Europe.
The European Institute of Oncology reported results of a
phase I/II trial in which patients with tumours <2.5 cm
(n = 84) were treated with electron beam IORT alone after
lumpectomy with a 1 cm margin [12]. A PTV of 1–3 cm
around the clinical tumour bed was chosen. Doses were
escalated from 17 to 21 Gy. Acute toxicity was minimal, with
grade 1–2 fibrosis occurring in 5% receiving 21 Gy. It was
concluded that the technique is feasible; it is being evaluated
in a randomized study against WBRT. A similar study112
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conducted at University College Hospital, London employed
IORT with soft X-rays at the time of lumpectomy [13]. This
system uses a miniature electron beam-driven X-ray source
called INTRABEAM (PeC) that emits soft X-rays (50 kV) from
within the breast. The X-rays are emitted from the tip of a
10 cm × 3.2 mm diameter probe, which is enclosed in a
spherical applicator (available in 2.5–5 cm diameter sizes),
which in turn is inserted in the tumour bed and IORT is
delivered over about 25 min. The prescribed dose is 5 and
20 Gy at 1 cm and 0.2 cm, respectively, from the tumour bed.
The biologically effective dose is calculated to be 7–53 Gy
for α/β = 10 and 20–120 Gy for α/β = 1.5. Quick attenuation
of radiation reduces the damage to normal tissues and allows
radiotherapy to be delivered in a standard operating theatre.
Concerns have been raised that the biological equivalent
dose for these IORT systems may be too low for tumour
effect and too ‘hot’ for normal tissues. Further criticisms of
these techniques include lack of knowledge of resection
margins or node status before therapy. Most importantly, we
currently know little of the biological effect of large single,
high dose rate treatments on microscopic breast cancer, and
the current study designs will not elucidate the optimal
dosing.
Keisch [4] cited recently published studies of APBI with
median follow up of at least 5 years. Although local
recurrence rates in two of these studies of 1.2–2.0% are very
promising, a third study, with a recurrence rate of 4.4%, might
be regarded as less satisfactory. A recent study of
lumpectomy with or without WBRT, conducted in women
older than 70 years with tumour size <2 cm and oestrogen
receptor positive, yielded local recurrence rates of 4%
without any radiotherapy, which were reduced significantly to
1% with WBRT. This raised questions regarding the need for
any adjuvant radiotherapy in carefully selected subgroups of
patients with cancers of good prognosis. Clinicians must
bear in mind that for many women avoidance of local
recurrence of breast cancer, even if manageable by
mastectomy, is paramount. In a recent study conducted by
Fyles and coworkers [14], 899 out of 1572 patients (57%)
refused randomization after lumpectomy to radiotherapy or
tamoxifen alone. Hence, future randomized studies of WBRT
versus APBI will need to demonstrate greater efficacy than
surveillance with anti-oestrogen treatment in this particular
group.
Conclusion
The PBI approach offers potentially the most significant
advance since breast conservation became the standard of
care. It seems highly likely that future generations of women
with early breast cancer will receive focal tumour bed
irradiation, with excellent breast conservation rates and
improved uncomplicated cure rates. A major factor in favour
of APBI currently appears to be patient convenience, and it is
therefore vital that proper evaluation of the technology be
done within the context of well designed, randomized clinical
trials, in which standard whole breast irradiation techniques
are compared with more innovative tests of target size
definition and fractionation. We must still define those patient
groups most likely to benefit from PBI. Premature and
empirical adoption of the technology without the results of
such studies is likely to set back the entire field.
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